Regions – Page 46 – pharmaceutical daily

December 10, 2021 Off

Moderna’s Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains

Moderna today announced the first positive interim data from the Phase 1 study of the Company’s quadrivalent seasonal flu vaccine candidate, mRNA-1010, as it successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults.

December 10, 2021 Off

Vifor Pharma and Angion phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury misses goal

By BusinessWire

Vifor Pharma and Angion Biomedica’s exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).

December 10, 2021 Off

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

By Dino Mustafić

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18y and above, across six countries.

December 8, 2021 Off

New finding shows that Pfizer’s Covid-19 vaccine can partially protect from the Omicron variant of the virus

By Dino Mustafić

New finding shows that Pfizer’s Covid-19 vaccine can partially protect from the Omicron variant of the virus.

December 7, 2021 Off

Medicago and GSK receive good news for its plant-based COVID-19 vaccine candidate

By Dino Mustafić

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have received positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

December 7, 2021 Off

Pure Tech kicks off study for its neuro conditions treatment candidate

By Dino Mustafić

PureTech Health has kicked off a clinical study of LYT-300 (oral allopregnanolone), its wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 is the third clinical-stage, wholly-owned candidate from PureTech’s pipeline.

December 7, 2021 Off

Bavarian Nordic A/S issues 6,373,680 New Ordinary Shares

By GlobeNewswire

Bavarian Nordic A/S (“Bavarian Nordic” or the “Company”) announced its intention to raise new capital through an accelerated bookbuilding process.…

October 12, 2021 Off

Hikma launches Micafungin for Injection

By Dino Mustafić

Hikma Pharmaceuticals has announced it launched Micafungin for Injection through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 50mg and 100mg doses.

October 11, 2021 Off

Sandoz completes acquisition of GSK’s cephalosporin business

By Dino Mustafić

Sandoz, a Novartis division, has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets,…

October 5, 2021 Off

Merck to seek emergency use authorization for Molnupiravir, oral antiviral medicine for COVID-19

By Dino Mustafić

The drug maker Merck said it plans to seek emergency use authorization in the U.S. as soon as possible and to submit applications to regulatory agencies worldwide for Molnupiravir, which could be the first oral antiviral medicine for COVID-19.